Phase I/II Trial of SPK-8011: Stable and Durable FVIII Expression for > 2 Years With Significant ABR Improvements in Initial Dose Cohorts Following AAV-Mediated FVIII Gene Transfer for Hemophilia A
PDF) A Phase 1/2 Trial of Investigational Spk-8011 in Hemophilia a Demonstrates Durable Expression and Prevention of Bleeds
Spark Therapeutics, Inc. (ONCE)
A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells | Nature Biotechnology
Spark slides on hemophilia A data, aims for phase 3 | Fierce Biotech
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A | NEJM
Dia 1
Phase I/II Trial of SPK-8011: Stable and Durable FVIII Expression for > 2 Years With Significant ABR Improvements in Initial Dose Cohorts Following AAV-Mediated FVIII Gene Transfer for Hemophilia A
Phase I/II Trial of SPK-8011: Stable and Durable FVIII Expression for > 2 Years With
INVESTIGATIONAL GENE THERAPY RESEARCH STUDIES FOR HEMOPHILIA
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A | NEJM
Investigational gene therapy leads to sustained factor VIII expression in hemophilia A
Gene Therapy for Hemophilia - ppt download
Document Spark Therapeutics, Inc. 2019 Current Report 8-K
Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A: Molecular Therapy - Methods & Clinical Development
The intersection of vector biology, gene therapy, and hemophilia - Lisowski - 2021 - Research and Practice in Thrombosis and Haemostasis - Wiley Online Library
Novel gene therapy for hemophilia A | Penn Today
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A | NEJM
From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1 - Pediatric Neurology
Potential Gene Therapy SPK-8011 Fares Well in Hemophilia A Study
Phase I/II Trial of SPK-8011: Stable and Durable FVIII Expression for >2 Years with Significant ABR Improvements in Initial Dose Cohorts Following AAV-Mediated FVIII Gene Transfer for Hemophilia A - ISTH Congress
Gene Therapy for Hemophilia: Progress and Setbacks
Inside Spark Therapeutics Investigational SPK-8011 for Hemophilia A with Dr Tiffany Chang
Hemophilia A Clinical Gene Therapy Trials (September 2020). Listed are... | Download Scientific Diagram
Phase I/II Trial of SPK-8011: Stable and Durable FVIII Expression for > 2 Years With Significant ABR Improvements in Initial Dose Cohorts Following AAV-Mediated FVIII Gene Transfer for Hemophilia A
